E. A. Kiseleva, S. Krylova, T. N. Povet`eva, Y. Nesterova, O. G. Afanas`eva, P. V. Kul`pin, D. A. Kulagina, E. Zueva, N. Suslov, V. V. Eremina, O. Baibakova, S. Sysolyatin, V. V. Zhdanov
{"title":"六氮杂唑脲酮类新分子抗伤性的研究","authors":"E. A. Kiseleva, S. Krylova, T. N. Povet`eva, Y. Nesterova, O. G. Afanas`eva, P. V. Kul`pin, D. A. Kulagina, E. Zueva, N. Suslov, V. V. Eremina, O. Baibakova, S. Sysolyatin, V. V. Zhdanov","doi":"10.33647/2074-5982-19-1-61-72","DOIUrl":null,"url":null,"abstract":"In this work, we studied the pharmacological activity of a newly-synthesized compound 4-(3,4- dibromothiophenylcarbonyl)-10-(2-ethoxyacetyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,03,11,05,9]dodecane (M3) using somatogenic pain models of various genesis (thermal and visceral pain, mechanical compression of a paw). The compound showed a high antinociceptive efficacy, comparable to or exceeding that of tramadol. It was shown that the new molecule from the class of hexaazaisowurtzitane effectively blocks nociceptive reactions at the supraspinal and peripheral levels of pain sensitivity organization. The results obtained confirm the possibility of creating new pharmacologically active molecules based on the high-energy substance of hexaazaisowurtzitane, which is a priority in domestic pharmaceutical production.","PeriodicalId":14837,"journal":{"name":"Journal Biomed","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study Into Antinociceptive Activity of a New Molecule from the Class of Hexaazaizowurzitane\",\"authors\":\"E. A. Kiseleva, S. Krylova, T. N. Povet`eva, Y. Nesterova, O. G. Afanas`eva, P. V. Kul`pin, D. A. Kulagina, E. Zueva, N. Suslov, V. V. Eremina, O. Baibakova, S. Sysolyatin, V. V. Zhdanov\",\"doi\":\"10.33647/2074-5982-19-1-61-72\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this work, we studied the pharmacological activity of a newly-synthesized compound 4-(3,4- dibromothiophenylcarbonyl)-10-(2-ethoxyacetyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,03,11,05,9]dodecane (M3) using somatogenic pain models of various genesis (thermal and visceral pain, mechanical compression of a paw). The compound showed a high antinociceptive efficacy, comparable to or exceeding that of tramadol. It was shown that the new molecule from the class of hexaazaisowurtzitane effectively blocks nociceptive reactions at the supraspinal and peripheral levels of pain sensitivity organization. The results obtained confirm the possibility of creating new pharmacologically active molecules based on the high-energy substance of hexaazaisowurtzitane, which is a priority in domestic pharmaceutical production.\",\"PeriodicalId\":14837,\"journal\":{\"name\":\"Journal Biomed\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal Biomed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33647/2074-5982-19-1-61-72\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Biomed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33647/2074-5982-19-1-61-72","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Study Into Antinociceptive Activity of a New Molecule from the Class of Hexaazaizowurzitane
In this work, we studied the pharmacological activity of a newly-synthesized compound 4-(3,4- dibromothiophenylcarbonyl)-10-(2-ethoxyacetyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,03,11,05,9]dodecane (M3) using somatogenic pain models of various genesis (thermal and visceral pain, mechanical compression of a paw). The compound showed a high antinociceptive efficacy, comparable to or exceeding that of tramadol. It was shown that the new molecule from the class of hexaazaisowurtzitane effectively blocks nociceptive reactions at the supraspinal and peripheral levels of pain sensitivity organization. The results obtained confirm the possibility of creating new pharmacologically active molecules based on the high-energy substance of hexaazaisowurtzitane, which is a priority in domestic pharmaceutical production.